Overview

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

Status:
Completed

Trial end date:
2016-07-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.

Phase:

Phase 3

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Melphalan
Prednisone
Thalidomide